Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, Alexander JK, Barkay H, Harary E. Coffey B, et al. Among authors: barkay h. JAMA Netw Open. 2021 Oct 1;4(10):e2129397. doi: 10.1001/jamanetworkopen.2021.29397. JAMA Netw Open. 2021. PMID: 34661664 Free PMC article. Clinical Trial.
A phase II study of laquinimod in Crohn's disease.
D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. D'Haens G, et al. Among authors: barkay h. Gut. 2015 Aug;64(8):1227-35. doi: 10.1136/gutjnl-2014-307118. Epub 2014 Oct 3. Gut. 2015. PMID: 25281416 Free PMC article. Clinical Trial.
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, Alexander J, Barkay H, Harary E. Jankovic J, et al. Among authors: barkay h. JAMA Netw Open. 2021 Oct 1;4(10):e2128204. doi: 10.1001/jamanetworkopen.2021.28204. JAMA Netw Open. 2021. PMID: 34609495 Free PMC article. Clinical Trial.
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Hauser RA, Barkay H, Fernandez HH, Factor SA, Jimenez-Shahed J, Gross N, Marinelli L, Wilhelm A, Alexander J, Gordon MF, Savola JM, Anderson KE. Hauser RA, et al. Among authors: barkay h. Front Neurol. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. Front Neurol. 2022. PMID: 35280262 Free PMC article.
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Harary E, Alexander J, Barkay H, Gordon MF. Jankovic J, et al. Among authors: barkay h. Mov Disord Clin Pract. 2023 Aug 24;10(9):1388-1398. doi: 10.1002/mdc3.13849. eCollection 2023 Sep. Mov Disord Clin Pract. 2023. PMID: 37772282 Free PMC article.
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: barkay h. Neurol Ther. 2024 Jun;13(3):655-675. doi: 10.1007/s40120-024-00600-1. Epub 2024 Apr 1. Neurol Ther. 2024. PMID: 38557959 Free PMC article.
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Hauser RA, Barkay H, Fernandez HH, Jimenez-Shahed J, Factor SA, Gross N, Marinelli L, Gordon MF, Barash S, Finkbeiner S, Chaijale N, Anderson KE. Hauser RA, et al. Among authors: barkay h. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21. J Clin Psychopharmacol. 2024. PMID: 38901008
Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: barkay h. Neurol Ther. 2024 Dec;13(6):1747-1749. doi: 10.1007/s40120-024-00660-3. Neurol Ther. 2024. PMID: 39266813 Free PMC article. No abstract available.
13 results